uploads/2018/06/Neurosciences.png

An Update on JNJ’s Neuroscience Business after Q1 2018

By

Updated

Neuroscience segment’s revenue trends

In the first quarter, Johnson & Johnson’s (JNJ) Neuroscience business reported revenues of $1.6 billion compared to $1.5 billion in the first quarter of 2017, which reflected ~4.1% YoY (year-over-year) growth.

In the US and international markets, Johnson & Johnson’s (JNJ) Neuroscience segment generated first-quarter revenues of $624.0 million and $935.0 million, respectively. This compared to revenues of $664.0 million and $833.0 million in the first quarter of 2017, which reflected an ~6.0% decline and ~12.2% growth on a YoY basis.

Article continues below advertisement

Concreta’s revenue trends

In the first quarter, Concreta generated revenues of $173.0 million compared to $209.0 million in the first quarter of 2017, which is an ~17.0% YoY decline.

In the US and international markets, Concreta reported first-quarter revenues of $66.0 million and $107.0 million, respectively. It reported revenues of $108.0 million and $101.0 million in the first quarter of 2017, reflecting an ~38.9% YoY decline and ~5.9% YoY growth. The availability of generic versions of Concreta in the US market contributed to the decline of Concreta revenues in the first quarter.

Invega Sustenna/Xeplion/Trinza/Trevicta: Revenue trends

Johnson & Johnson’s Invega Sustenna/Xeplion/Trinza/Trevicta witnessed 15.2% growth to reach revenues of $696.0 million in the first quarter, including revenues of $400.0 million and $296.0 million in the US and international markets.

In the US and international markets, Johnson & Johnson’s Invega Sustenna/Xeplion/Trinza/Trevicta witnessed ~7.5% and 27.6% YoY growth, respectively, in the first quarter. Invega Sustenna is used for the treatment of schizophrenia.

Article continues below advertisement

Risperdal Consta: Revenue trends

Johnson & Johnson’s Risperdal Consta reported first-quarter revenues of $196.0 million compared to $207.0 million in the first quarter of 2017, which is ~5.3% YoY growth.

In the US and international markets, Risperdal Consta generated first-quarter revenues of $82.0 million and $114.0 million, respectively, which is an ~13.7% YoY decline and ~1.8% YoY growth. Risperdal Consta is used in the treatment of schizophrenia and long-term therapy for individuals with Bipolar I disorder.

Johnson & Johnson’s Risperdal Consta and Invega Sustenna face stiff competition from Eli Lilly’s (LLY) Zyprexa, AstraZeneca’s (AZN) Seroquel, and Allergan’s (AGN) Saphris. Zyprexa, Seroquel XR, and Saphris reported revenues of $122.6 million, $53.0 million, and $33.0 million, respectively, in the first quarter.

Advertisement

More From Market Realist